Abstract: A wireless power transmission resonator using a conducting wire with a vertical rectangular cross-section is disclosed. The wireless power transmission resonator may include a first element including a first element upper part arranged in an upper end of a resonator and a first element lower part arranged in a lower end of the resonator, wherein the first element upper part and the first element lower part each may include a spiral layer having a spiral structure that is wound to face a wide surface of a conducting wire including a vertical rectangular cross-section and a second element arranged in a center of the resonator and between the first element upper part and the first element lower part and including a spiral layer having a spiral structure that is wound to face the wide surface of the conducting wire including the vertical rectangular cross-section.

Abstract: A read pattern obtained in a read operation for determining an optimal read voltage when an initial read operation fails is stored, and is used in a read operation to be subsequently performed for determining a new optimal read voltage.

Abstract: A method for intelligent dynamic frequency resource management, the method includes the steps of: generating a sensing table indicating presence or absence of existing users by sensing a spectrum in an interfering earth station adjacent to a wanted receiving earth station in a situation of satellite communications between a wanted space station and the wanted receiving earth station, generating a backup channel list for idle channel inference by using the generated sensing table, checking whether the existing users exist in any one communication channel through spectrum sensing for the generated backup channel list, and inferring the communication channel as an idle channel and transmitting the communication channel to an interfering space station adjacent to the wanted space station in a case where there are no existing users, wherein in low-orbit satellite communication systems, frequency resources not in use temporally or regionally may be flexibly used.

Abstract: An apparatus configured to manufacture a display device and a method of manufacturing a display device include a stage configured to place a process target object on an upper surface thereof; a bending head in contact with the process target object to bend the process target object; a distance measurement sensor installed above the stage to be movable in a horizontal direction; and a cylinder configured to adjust a vertical position of the bending head.

Abstract: The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.

Abstract: Provided is a method of preparing a (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one, and a (5R)-2-hexyl-5-hydroxy-3-iminohexadecanoate derivative used in said method as an intermediate.

Abstract: The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.

Abstract: Provided is a method of preparing a (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one, and a (5R)-2-hexyl-5-hydroxy-3-iminohexadecanoate derivative used in said method as an intermediate.

Abstract: The present invention relates to a method for preparing clopidogrel 1,5-naphthalenedisulfonate or a hydrate thereof, which comprises reacting a clopidogrel-acid addition salt with disodium 1,5-naphthalenedisulfonate or its hydrate in water, or a mixture of water and an organic solvent. High quality clopidogrel 1,5-naphthalenedisulfonate can be prepared by the inventive method by way of using non-corrosive disodium 1,5-naphthalenedisulfonate.

Abstract: The present invention relates to a method for preparing clopidogrel 1,5-naphthalenedisulfonate or a hydrate thereof, which comprises reacting a clopidogrel-acid addition salt with disodium 1,5-naphthalenedisulfonate or its hydrate in water, or a mixture of water and an organic solvent. High quality clopidogrel 1,5-naphthalenedisulfonate can be prepared by the inventive method by way of using non-corrosive disodium 1,5-naphthalenedisulfonate.

Abstract: Azithromycin is prepared in a high yield by a simple process using a crystalline 9-deoxo-9a-aza-9a-homoerythromycin A hydrate.

Abstract: High purity Form II crystals of clarithromycin can be easily prepared in a high yield by a process comprising the steps of: protecting the 9-oxime hydroxy group of erythromycin A 9-oxime or a salt thereof with a tropyl group and the 2′- and 4″-hydroxy groups with trimethylsilyl groups; reacting 2′,4″-O-bis(trimethylsilyl)erythromycin A 9-O-tropyloxime with a methylating agent; removing the protecting groups and the oxime group of 2′,4″-O-bis(trimethylsilyl)-6-O-methylerythromycin A 9-O-tropyloxime to obtain crude clarithromycin; treating the crude clarithromycin with methanesulfonic acid in a mixture of a water-miscible organic solvent and water to obtain crystalline clarithromycin mesylate trihydrate; and neutralizing the crystalline clarithromycin mesylate trihydrate with aqueous ammonia in a mixture of a water-miscible organic solvent and water.

Abstract: High purity Form II crystals of clarithromycin can be easily prepared in a high yield by a process comprising the steps of: protecting the 9-oxime hydroxy group of erythromycin A 9-oxime or a salt thereof with a tropyl group and the 2′- and 4″-hydroxy groups with trimethylsilyl groups; reacting 2′,4″-O-bis(trimethylsilyl)erythromycin A 9-O-tropyloxime with a methylating agent; removing the protecting groups and the oxime group of 2′,4″-O-bis(trimethylsilyl)-6-O-methylerythromycin A 9-O-tropyloxime to obtain crude clarithromycin; treating the crude clarithromycin with methanesulfonic acid in a mixture of a water-miscible organic solvent and water to obtain crystalline clarithromycin mesylate trihydrate; and neutralizing the crystalline clarithromycin mesylate trihydrate with aqueous ammonia in a mixture of a water-miscible organic solvent and water.